Alignment Healthcare Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alignment Healthcare, Inc.

KSF has opened an investigation into Alignment Healthcare following a former executive’s lawsuit alleging the company misclassified $8 million to $10 million in operating expenses as capital expenditures to inflate adjusted EBITDA; these claims have not been established as fact. Separately, CMS downgraded Alignment’s H3815 contract to a 3.5 Star Rating on October 8, making it ineligible for quality bonus payments in fiscal 2028. The article says Alignment shares declined precipitously after the disclosures but gives no percentage or price figure.

Analysis

The durable issue is the contract-level Star Rating downgrade, not the plaintiff firm’s announcement. Loss of quality-bonus eligibility in FY2028 could constrain benefits or pricing competitiveness for the affected plan, risking enrollment and retention; the extent of the consolidated impact cannot be assessed without H3815 membership, revenue contribution, and management’s forecast. If competitors gain enrollment in overlapping markets, the effect could extend beyond the direct bonus loss. The alleged $8–10 million expense classification raises a separate credibility risk: if substantiated, investors may discount adjusted EBITDA and demand stronger controls or audited reconciliation. The allegation is not a finding, and a law-firm investigation alone does not establish a restatement or liability.

Near term, the investigation announcement is a weak standalone catalyst after the reported share-price decline. Over the next 1–3 months, watch for company disclosures, auditor or regulator action, and guidance that quantifies the rating impact. Over 6–18 months, enrollment, benefit competitiveness, and any further rating changes determine whether the FY2028 issue becomes a persistent growth or margin headwind. The contrarian point: litigation headlines may be over-weighted relative to the operational rating risk, which is more measurable but delayed. A CMS reversal or improved ratings would weaken the downside thesis; evidence of expense reclassification, revised results, or worsening enrollment would strengthen it.

Key Decisions for Investors

• Do not initiate a short solely on KSF’s announcement. For existing ALHC exposure, keep sizing conservative until the company provides a contract-level estimate of the FY2028 bonus and enrollment exposure.
• Underweight ALHC versus a diversified healthcare-services benchmark if the next guidance or enrollment update confirms material H3815 pressure; avoid chasing the already-reported selloff without valuation and liquidity data.
• Set alerts for restated or reconciled adjusted EBITDA, auditor/regulatory developments, CMS appeal outcomes, H3815 membership trends, and management guidance. These are the evidence points that would change the thesis.
• Before taking a directional options position, verify implied volatility and the next earnings/event calendar; the supplied information does not establish that options offer favorable risk/reward.